X4 PHARMACEUTICALS, INC Current State and Local Tax Expense (Benefit)
X4 PHARMACEUTICALS, INC (XFOR) reported Current State and Local Tax Expense (Benefit) of $13.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC current state and local tax expense (benefit) for the quarter ending 2024-03-31 was $0.00.
- X4 PHARMACEUTICALS, INC current state and local tax expense (benefit) for the quarter ending 2023-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC current state and local tax expense (benefit) for the quarter ending 2023-06-30 was $0.00.
- X4 PHARMACEUTICALS, INC current state and local tax expense (benefit) for the quarter ending 2023-03-31 was $0.00.
- X4 PHARMACEUTICALS, INC current state and local tax expense (benefit) for fiscal 2025 was $13.00K.
| Period end | Current State and Local Tax Expense (Benefit) 3 month | Current State and Local Tax Expense (Benefit) 6 month | Current State and Local Tax Expense (Benefit) 9 month | Current State and Local Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $13.00K 10-K · filed 2026-03-17 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $0.00 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 | $0.00 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |